Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy

Circulation

Volumn 94, Issue 4, 1996, Pages 614-621

  Waters, David ^a   Lespérance, Jacques ^a   Gladstone, Peter ^a   Boccuzzi, Stephen J ^a   Cook, Thomas ^a   Hudgin, Roger ^a   Krip, Gordon ^a   Higginson, Lyall ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

atherosclerosis; coronary disease; smoking

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; BEHAVIOR MODIFICATION; CANADA; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING CESSATION;

EID: 0029758534     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.4.614     Document Type: Article

References (63)

1. English JP, Willius FA, Berkson J. Tobacco and coronary disease. JAMA. 1940;115:1327-1329.
2. Reducing the Health Consequences of Smoking: 25 Years of Progress: A Report of the Surgeon General: Executive Summary. Rockville, Md: US Department of Health and Human Services; 1989 (DHHS Publication No. [CDC] 89-8411).
3. Bartecchi CE, MacKenzie TD, Schrier RW. The human cost of tobacco use. N Engl J Med. 1994;330:907-912, 975-980.
4. Sparrow D, Dawber TR, Colton T. The influence of cigarette smoking on prognosis after a first myocardial infarction. J Chron Dis. 1978;31:425-432.
5. Vlietstra RE, Kronmal RA, Oberman A, Frye RL, Killip T. Effect of cigarette smoking on survival of patients with angiographically documented coronary artery disease. JAMA. 1986;255:1023-1027.
6. Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med. 1986;314;271-275.
7. Barry J, Mead K, Nabel EG, Rocco MB, Campbell S, Fenton T, Mudge GH Jr, Selwyn AP. Effect of smoking on the activity of ischemic heart disease. JAMA. 1989;261:398-402.
8. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO, for the CASS Investigators. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. J Am Coll Cardiol. 1992;2:287-294.
9. Davis J, Shelton L, Eigenberg D. Hignite C, Watananon-tobaccobe I. Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther. 1985;37:529-533.
10. Davis J, Shelton L, Watanabe I, Arnold P. Passive smoking affects endothelium and platelets. Arch Intern Med. 1989;149:386-389.
11. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation. 1987;76:6-14.
12. McBride PE. The health consequences of smoking: cardiovascular diseases. Med Clin North Am. 1992;76:333-353.
13. Klein LW, Ambrose J, Pichard A, Holt J, Gorlin R, Teichholz LE. Acute coronary hemodynamic response to cigarette smoking in patients with coronary artery disease. J Am Coll Cardiol. 1984;3:879-886.
14. Nicod P, Rehr R, Winniford MD, Campbell WB, Firth BG, Hillis LD. Acute systemic and coronary hemodynamic and serologic responses to cigarette smoking in long-term smokers with atherosclerotic coronary artery disease. J Am Coll Cardiol. 1984;4:964-971.
15. Scholl JM, Benacerraf A, Ducimetiere P, Chabas D, Brau J, Chapelle J, Thery JL. Comparison of risk factors in vasospastic angina without significant fixed coronary narrowing to significant fixed coronary narrowing and no vasospastic angina. Am J Cardiol. 1986;57:199-202.
16. Aronow W. Effect of passive smoking on angina pectoris. N Engl J Med. 1978;299:21-24.
17. Muscat JE, Harris RE, Haley NJ, Wynder EL. Cigarette smoking and plasma cholesterol. Am Heart J. 1991;121:141-147.
18. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 1987;75:124-130.
19. Bemis CE, Gorlin R, Kemp HG, Herman MV, Progression of coronary artery disease: a clinical arteriographic study. Circulation. 1973; 47:455-464.
20. Kramer JR, Matsuda Y, Mulligan JC, Aronow M, Proudfit WL. Progression of coronary atherosclerosis. Circulation. 1981;63:519-526.
21. Vanhaecke J, Piessens J, Van de Werf F, Willems JL, De Geest H. Angiographic evolution of coronary atherosclerosis in non-operated patients. Eur Heart J. 1983;4:547-556.
22. Moise A, Théroux P, Taeymans Y, Waters DD, Lespérance J, Fines P, Descoings B, Robert P. Clinical and angiographic factors associated with progression of coronary artery disease. J Am Coll Cardiol. 1984;3:659-667.
23. Shea S, Sciacca RR, Esser P, Han J, Nichols AB. Progression of coronary atherosclerotic disease assessed by cinevideodensitometry: relation to clinical risk factors. J Am Coll Cardiol. 1986;8:1325-1331.
24. Benchimol D, Benchimol H, Bonnet J, Dartigues JF, Couffinhal T, Bricaud H. Risk factors for progression of atherosclerosis six months after balloon angioplasty of coronary stenosis. Am J Cardiol. 1990;65:980-985.
25. Nobuyoshi M, Tanaka M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, Kim K, Shindo T, Kimura K. Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol. 1991;18:904-910.
26. Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, Bourassa MG, and the CASS participating investigators and staff. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol. 1993;22:1141-1154.
27. Raichlen JS, Healy B, Achuff SC, Pearson TA. Importance of risk factors in the angiographic progression of coronary artery disease. Am J Cardiol. 1986;57:66-70.
28. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
29. Ornish D, Brown S, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.
30. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
31. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hoberg E, Drinkmann A, Bacher F, Grunze M, Kubler W. Regular physical exercise and low fat diet: effect on progression of coronary artery disease. Circulation. 1992;86:1-11.
32. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 1994;344:1182-1186.
33. Levy RI, Brensike JF, Epstein SE, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarity DJ, Fisher ML, Friedman L, Friedewald W, Detre KM. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:325-337.
34. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston A, Smink RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castenada-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia, N Engl J Med. 1990;323:946-955.
35. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoor LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
36. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. The effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
37. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
38. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
39. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-1298.
40. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:565-569.
41. 4L Lichtlen PR, Nikutta P, Jost S, Deckers J, Wiese B, Rafflenbeul W, and the INTACT Study Group. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitative coronary arteriography: relation to clinical events and risk factors. Circulation. 1992;86:828-838.
42. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Boccuzzi SJ. Lespérance J, CCAIT Study Group. Effects of monotherapy with an HMG CoA reductase inhibitor upon the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation. 1994;89:959-968.
43. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Lespérance J. Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Control Clin Trials. 1993;14:45-74.
44. Reiber JHC, van der Zwet PMJ, von Land CD, Koning G, Loois G, Zorn I, van den Brand M, Gerbrands JJ. On-line quantification of coronary angiograms with the DCI system. Medicamundi. 1989;34:89-98.
45. Waters D, Lespérance J, Craven T, Hudon G, Gillam LD. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis: implications for clinical trials. Circulation. 1993;87(suppl II):II-38-II-47.
46. Moise A, Lespérance J, Théroux P, Taeymans Y, Goulet C, Bourassa MG. Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: analysis of 313 nonoperated patients. Am J Cardiol. 1984;54:1176-1181.
47. Buja LM, Willerson JT. Clinicopathologic correlates of acute ischemic heart disease syndromes. Am J Cardiol. 1981;47:343-356.
48. Moise A, Théroux P, Taeymans Y, Descoings B, Lespérance J, Waters DD, Pelletier GB, Bourassa MG. Unstable angina and progression of coronary atherosclerosis. N Engl J Med. 1983;309:685-689.
49. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borneo S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56-62.
50. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
51. Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Pearce MB, Bissett JK, Edmiston WA, Sawin HS Jr, Weber FJ, Varco RL, Campbell GS, Yellin AE, Smink RD Jr, Long JM, Hansen BJ, Chalmers TC, Meier P, Stamler J, for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
52. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhorn DH, Hodis HN. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation. 1996;93:34-41.
53. Moise A, Clement B, Saltiel J. Clinical and angiographic correlates and prognostic significance of the coronary extent score. Am J Cardiol. 1988;61:1255-1259.
54. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
55. Taeymans Y, Théroux P, Lespérance J, Waters D. Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation. 1992;85:78-85.
56. Falk E. Why do plaques rupture? Circulation. 1992;86(suppl III):III-30-III-42.
57. Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, Buhler FR. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation. 1994;90:27-34.
58. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510-2516.
59. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish D, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
60. Gilligan DM, Quyyumi AA, Cannon RO, Johnson GB, Schenke WH. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
61. Kjekshus J, Pedersen T, Pyorala K, for the 4S Group. Impact of hypertension, diabetes, and smoking on the effect of simvastatin on coronary events in coronary heart disease patients. Circulation. 1995;92(suppl I):I-18. Abstract.
62. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
63. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.